Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase I, open-label, randomized, three-way crossover trial evaluating the efficacy, safety, pharmacokinetics and tolerability of two fixed-dose combinations (FDC) of Darunavir/Cobicistat (G003 and G004) versus Darunavir and Ritonavir in healthy volunteers.

Next Previous
Trial Profile

A phase I, open-label, randomized, three-way crossover trial evaluating the efficacy, safety, pharmacokinetics and tolerability of two fixed-dose combinations (FDC) of Darunavir/Cobicistat (G003 and G004) versus Darunavir and Ritonavir in healthy volunteers.

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 05 Dec 2015

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cobicistat/darunavir (Primary) ; Darunavir; Ritonavir
  • Indications HIV infections; HIV-1 infections
  • Focus Adverse reactions; Pharmacokinetics
  • Acronyms TMC114IFD1001
  • Sponsors Janssen Research & Development

Most Recent Events

  • 05 Dec 2015 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top